Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Apellis Pharmaceuticals, Inc.

http://www.apellis.com/

Latest From Apellis Pharmaceuticals, Inc.

Finance Watch: Public Markets Open Back Up For Biopharma Offerings

Public Company Edition: An IPO and three big follow-on offerings hit the market but other public companies revealed plans to cut costs or reprioritize their R&D pipelines, signaling that uncertainty remains. 

Financing Strategy

Apellis Has New Hope for Pegcetacoplan With Longer-Term Data

One of two Phase III trials for pegcetacoplan in geographic atrophy previously failed, but 18-month data showed statistically significant and possibly accelerating improvement.

Ophthalmic Business Strategies

Nine Major Approval Decisions To Watch In Early 2022

Nine prominent drug candidates are awaiting an FDA approval decision in the next few months. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the potential launches likely to shake up the market from HIV to wet AMD.

Drug Review Companies

Beam Anticipates Pfizer Deal Will Lead To Additional Partnerships

The $300m upfront payment should provide considerable runway for the base-editing company, which also plans multiple IND filings and enrolling the first patient in its sickle cell study this year.

Business Strategies Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register